INHIBITOR of Cytotoxic T-lymphocyte protein 4 inhibitor
Product Description
Zalifrelimab (anti-CTLA-4) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab (anti-CTLA-4) antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
26.6 kDa (Light Chain) & 52.5 kDa (Heavy Chain), under reducing conditions; 203.5 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2148321-69-9
Images
Zalifrelimab (anti-CTLA-4) (Ab182811) - Flow Cytometry huCTLA-4-CHO-K cells were stained with Zalifrelimab (anti-CTLA-4) (Ab182811) and negative control protein respectively, washed and then followed by PE and analyzed with the FACS EC
₅₀
is 0.51 μg/mL.
Zalifrelimab (anti-CTLA-4) (Ab182811) - ELISA Immobilized Recombinant Human CTLA-4 Protein (rp176276) at 1.0 μg/mL can bind Zalifrelimab (anti-CTLA-4) (Ab182811) with the EC
₅₀
of 26.83 ng/mL.
Zalifrelimab (anti-CTLA-4) (Ab182811) - SEC The purity of Zalifrelimab (anti-CTLA-4) (Ab182811) is more than 95% verified by HPLC.
Associated Targets
CTLA4Tclin Cytotoxic T-lymphocyte protein 4 0 Activities